New pain meds pose tricky PR test, as FDA gaffe shows
Reformulations of prescription pain drugs designed to reduce abuse potential are arriving on the scene, and the FDA is grappling with the best way to encourage manufacturers to communicate risks vs. benefits and ensure safety.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.